WuXi AppTec Co., Ltd. - SIC # 8748 - BUSINESS CONSULTING SERVICES, NOT ELSEWHERE CLASSIFIED

Ticker Exchange SIC # Website Latest Ticker
WUXAY Over the counter 8748 www.wuxiapptec.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for WuXi AppTec Co., Ltd.

Top China Biopharma Stocks to Watch, According to Bernstein - Sep 30th, 2026 12:18 am
Pharmaceutical Impurity Synthesis and Isolation Services Report: Capitalize on a $2.1 Billion Market by 2030 as Tariffs and 8.9% Isolation Growth Reshape Competition Across Eurofins, WuXi AppTec, Cambrex and Charles River - Sep 29th, 2026 9:52 am
Contract Research Organization Services Market Forecasts Growth from $107.03B (2025) to $180.56B by 2030, Profiling IQVIA, Charles River, Syneos Health & WuXi AppTec - Sep 24th, 2026 7:01 am
Secure the Global Drug Discovery Services Report: Capitalize on AI-driven outsourcing and benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Syngene before rivals capture the next revenue wave - Sep 24th, 2026 2:02 am
Capitalize on Pharmacokinetics Outsourcing Disruption as Charles River, Labcorp, WuXi AppTec, Eurofins and Sygnature Compete to Dominate Drug Development ROI - Sep 23rd, 2026 3:55 am
Capitalize on the In Vivo Toxicology Shake-Up: Benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Thermo Fisher Before R&D Shifts Redraw Global Market Share - Sep 23rd, 2026 2:10 am
Capitalize on the Drug Discovery Outsourcing Shift: Benchmark Charles River, WuXi AppTec, Evotec, Labcorp and Sygnature to Secure R&D ROI and Outsmart the Global Market - Sep 23rd, 2026 2:08 am
Capitalize on the Toxicology Testing Services Market Shift: Benchmark Labcorp, Charles River, Eurofins, SGS and WuXi AppTec to Secure Growth and Outpace Disruption - Sep 23rd, 2026 2:06 am
Recent Price Trend in Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) is Your Friend, Here's Why - Sep 22nd, 2026 6:55 am
Capitalize on the ADME-Toxicology Testing Shift: Benchmark Charles River, Thermo Fisher, Eurofins, WuXi AppTec and Evotec to Accelerate R&D ROI and Outpace Disruption - Sep 22nd, 2026 2:18 am
Long-Acting Oligonucleotide Development: Dosing, Yield and Stability Questions - Sep 10th, 2026 5:00 am
Oligonucleotide Drug Delivery Is Moving Beyond the Liver - Sep 3rd, 2026 5:00 am
WuXi AppTec Continues to Reward Shareholders, Further Increasing Interim Dividend to RMB 1.51 Billion - Aug 30th, 2026 6:00 pm
Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) Is a Great Choice for 'Trend' Investors, Here's Why - Aug 27th, 2026 6:55 am
Here's Why Momentum in Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) Should Keep going - Aug 11th, 2026 6:55 am
Judge blocks US decision to add WuXi to list of firms tied to Chinese military - Aug 7th, 2026 1:20 pm
WuXi AppTec Delivers Strong H1 2026 Results and Raises Full-Year Guidance[1], Driven by Greater Success of Multiple Customers' Products and CRDMO Model - Aug 3rd, 2026 3:49 am
WuXi AppTec Named Constituent of the FTSE4Good Index Series for Fourth Consecutive Year - Jul 21st, 2026 6:00 pm
Integrated Development Helps Targeted Protein Degraders Reach the Clinic - Jul 6th, 2026 5:00 am
Complex Small Molecules Are Changing Drug R&D - Jun 26th, 2026 5:00 am